TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05947955: A Phase 2 Randomized Double-blind Placebo-controlled Study To Evaluate The Efficacy And Safety Of Adjunctive Recombinant Human Plasma Gelsolin With Standard Care For Moderate-to-Severe ARDS Due To Pneumonia Or Other Infections

Sponsor: BioAegis Therapeutics Inc. · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 600 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$5,145,000

Rescue Site Savings

+$3,410,400

Unlock Full NCT05947955 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05947955 Rescue Dossier →